Liver disease affects millions of patients each year. The field of regenerative medicine
promises alternative therapeutic approaches, including the potential to bioengineer …

BACKGROUND: New bioartificial liver devices are needed to supplement the limited supply
of organ donors available for patients with end-stage liver disease. Here, we report the …

The burden of liver diseases continues to grow worldwide, and liver transplantation is the
only option for patients with end‐stage liver disease. This procedure is limited by critical …

Liver synthetic and metabolic function can only be optimised by the growth of cells within a
supportive liver matrix. This can be achieved by the utilisation of decellularised human liver …

At this time, the only definitive treatment of hepatic failure is liver transplantation. However,
transplantation has been limited by the severely limited supply of human donor livers …

The resectable liver volume is strictly limited and this reduces the number of patients who
may be treated. Recently,“tissue/organ decellularization”, a new approach in …

Background & Aims: The therapy of choice for end-stage liver disease is whole-organ liver
transplantation, but this option is limited by a shortage of donor organs. Cell-based therapies …

Liver-like organoids that recapitulate the complex functions of the whole liver by combining
cells, scaffolds, and mechanical or chemical cues are becoming important models for …

As a result of significant progress made in the last years in developing methods of whole
organ decellularization techniques, organ bioengineering may now look more feasible than …

Liver transplantation from deceased or living human donors remains the only proven option
for patients with end-stage liver disease. However, the shortage of donor organs is a …